

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Use of tumour necrosis factor alpha (TNF α) inhibitors (adalimumab, certolizumab and infliximab [review]) and natalizumab for Crohn's disease

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Abbott Laboratories Ltd (adalimumab) • Elan Pharmaceuticals & Biogen Idec (natalizumab) • Schering Plough (infliximab) • UCB Pharma Ltd (formerly Celltech Pharmaceuticals Ltd) (certolizumab pegol) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Colostomy Association • CORE (formerly the Digestive Disorders Foundation) • National Association for Colitis and Crohn's Disease (NACC) • The Ostomy Lifestyle Centre • Specialised Healthcare Alliance • The Ileostomy Association <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Coloproctology of Great Britain and Ireland • Association of Surgeons of Great Britain and Ireland • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • AstraZeneca UK Ltd (budesonide) • Dr Falk Pharma UK Ltd (mesalazine, budesonide) • Ferring Pharmaceuticals Ltd (mesalazine) • Forest Laboratories UK Ltd (prednisolone) • GlaxoSmithKline (azathioprine, mercaptopurine) • IVAX Pharmaceuticals UK Ltd (mesalazine) • Mayne Pharma plc (methotrexate) • Meda Pharmaceuticals Ltd (hydrocortisone) • Novartis Pharmaceuticals Ltd (ciclosporin) • Pfizer Ltd (sulfasalazine) • Procter and Gamble Pharmaceuticals

National Institute for Health and Clinical Excellence
 Consultation on the tumour necrosis factor alpha (TNF α) inhibitors (adalimumab, certolizumab and infliximab) and natalizumab for Crohn's disease (review)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal Society of Medicine - Intellectual Disability Forum • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Bedfordshire PCT • Central and East Cheshire PCT • Department of Health • Welsh Assembly Government 	<p>(UK) Ltd (mesalazine)</p> <ul style="list-style-type: none"> • Sandoz Ltd (mesalazine, metronidazole) • Sanofi-Aventis Ltd (sodium cromoglicate, metronidazole) • Shire Pharmaceuticals Ltd (balsalazide sodium) • UCB Pharma Ltd (olsalazine sodium, prednisolone) • Winthrop Pharmaceuticals UK Ltd (metronidazole) • Wyeth Pharmaceuticals (methotrexate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • MRC Clinical Trials Unit <p><u>Assessment team</u></p> <ul style="list-style-type: none"> • National Coordinating Centre for Health Technology Assessment • West Midlands Health Technology Assessment Collaboration. <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Nursing & Supportive Care

National Institute for Health and Clinical Excellence
 Consultation on the tumour necrosis factor alpha (TNF α) inhibitors (adalimumab, certolizumab and infliximab) and natalizumab for Crohn's disease (review)

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).